PPIDT00411

Drug Information
NameTrastuzumab deruxtecan
SequenceNot Available
DrugBank_IDDB14962
Typebiotech
IndicationTrastuzumab deruxtecan is indicated for the following conditions: **HER2-Positive Breast Cancer** - This indication is approved in the US, Canada, and Europe. - It is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen.[L50662, L42240, L48576] In the US and Canada, it is used either in the metastatic setting or in the neoadjuvant or adjuvant setting in patients who have developed disease recurrence during or within six months of completing therapy.[L50662, L42240] - In Canada, it is also used in patients who have received prior treatment with trastuzumab emtansine (T-DM1).[L42240] **HER2-Low Breast Cancer** - This indication is approved in the US, Canada, and Europe. - It is indicated for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.[L50662, L42240, L48576] **Non-small cell lung cancer (NSCLC)** - This indication is approved in the US and Europe. - It is indicated for the treatment of adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have activating HER2 (ERBB2) mutations and who have received prior systemic therapy.[L50662, L48576] In Europe, it is used in patients who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.[L48576] **Gastric cancer** - This indication is approved in the US and Europe. - It is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.[L50662, L48576] **Solid Tumors** - This indication is approved in the US. - It is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumours who have received prior systemic treatment and have no satisfactory alternative treatment options.[L50662]
Dosage Forms
Form Route Strength
Injection, powder, for solution Intravenous
100 MG
Injection, powder, lyophilized, for solution Intravenous
100 mg/5mL
Powder, for solution Intravenous
100 mg / vial
Injection, solution, concentrate Intravenous
100 mg
Solution Intravenous
100 mg
Injection, powder, lyophilized, for solution Intravenous
10700000 mg
Target Information
Role Uniprot_ID Gene_Name Entity_Name Organism Actions Internal link
target P12314 FCGR1A High affinity immunoglobulin gamma Fc receptor I Homo sapiens antibody Link
target P11387 TOP1 DNA topoisomerase 1 Homo sapiens inhibitor Link
enzyme P10253 GAA Lysosomal alpha-glucosidase Homo sapiens substrate Link
enzyme P11387 TOP1 DNA topoisomerase 1 Homo sapiens inhibitor Link
enzyme P07858 CTSB Cathepsin B Homo sapiens substrate Link
enzyme P07711 CTSL Procathepsin L Homo sapiens substrate Link
enzyme P08684 CYP3A4 Cytochrome P450 3A4 Homo sapiens substrate Link
transporter P08183 ABCB1 ATP-dependent translocase ABCB1 Homo sapiens substrate Link
transporter Q9Y6L6 SLCO1B1 Solute carrier organic anion transporter family member 1B1 Homo sapiens unknown Link
transporter Q9NPD5 SLCO1B3 Solute carrier organic anion transporter family member 1B3 Homo sapiens substrate Link
transporter Q86VL8 SLC47A2 Multidrug and toxin extrusion protein 2 Homo sapiens substrate Link
transporter P33527 ABCC1 Multidrug resistance-associated protein 1 Homo sapiens substrate Link
transporter Q9UNQ0 ABCG2 Broad substrate specificity ATP-binding cassette transporter ABCG2 Homo sapiens substrate Link